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Abstract 
Addition of 12-O-tetradecanoylphorbol-13-acetate to RIE-1 rat intestinal epithelial cells stimulated arapid (mean 3-fold) increase in the subsequent 
binding of ‘251-labelled angiotensin II which was reversed or prevented when cellular protein kinase C was depleted. The increased binding was due, 
in part, to an up-regulation in the number of AT, angiotensin receptors on RIE-1 cells, without any signiticant change in their binding affinity. Since 
this rapid up-regulation was independent of receptor synthesis, it may result from an increased availability (to extracellular ligand) of preformed, 
but previously ‘cryptic’, AT, angiotensin receptors. 
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1. Introduction 
The investigation of cellular growth control has 
tended to focus on cultured fibroblastic cell lines such as 
Swiss 3T3 cells which respond mitogenically to activa- 
tion of various signalling pathways [1,2]. For example, 
polypeptide growth factors elicit mitogenic responses in 
these cells by activating receptor tyrosine kinases [3-61, 
whereas a variety of other mitogenic agonists share the 
ability to activate receptors that couple (via G proteins) 
to hydrolysis of phosphatidylinositol 4,5 bisphosphate 
(PIP,) [7]. However, in contrast to fibroblasts, the ag- 
onists and signalling pathways involved in regulating the 
proliferation of epithelial cells are less well characterised. 
In order to address this issue, we have investigated fac- 
tors that regulate proliferation in a cultured epithelial 
cell line (RIE-1) derived from the rat small intestine [8]. 
Like Swiss 3T3 cells, RIE-1 cells are stimulated to 
proliferate through the activation of receptor tyrosine 
kinases by polypeptide growth factors such as epidermal 
growth factor (EGF), insulin-like growth factor I (IGF- 
I) and insulin [9,10]. In order to investigate possible mi- 
togenic signalling via the inositol lipid pathway in RIE-1 
cells, we have recently identified the presence of AT, 
angiotensin receptors (which couple to PIP, hydrolysis) 
on these cells [11,12]. Activation of AT, receptors by 
angiotensin II (AII) was sufficient (in the absence of 
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co-administered polypeptide growth factors) to stimulate 
DNA synthesis and proliferation in RIE-1 cells [ 121. 
In view of their ability to mediate mitogenic signalling, 
I have begun to characterise the AT, receptors expressed 
by RIE-1 cells. Here, I demonstrate that activation of 
protein kinase C (PKC) by the phorbol ester, 12-0- 
tetradecanoylphorbol- 13-acetate (TPA), stimulates a 
rapid, protein synthesis-independent up-regulation in the 
number of AT1 receptors on RIE-1 cells. 
2. Materials and methods 
TPA and cycloheximide were from Sigma. DuP 753 and PD 123319 
were supplied by DuPont and Parke Davis, respectively. AI1 (Bachem) 
was iodinated using the soluble lactoperoxidase method [13]. RIE-1 
cells were maintained in culture in DMEM/S% newborn calf serum 
(ICN/Flow) as described [8] and grown to confluence in plastic dishes 
(Nunc) prior to experimental use. 
For [‘ZSI]AII binding assays, the cells were treated with test agents 
at 37°C as described in the individual figure legends. Cells were then 
washed three times with ice-cold binding medium (BM: PBS supple- 
mented with 0.1 pM KI and 0.1% (w/v) BSA) prior to overnight incu- 
bation at 4°C in BM containing [‘251]AII (0.5 nM). Non-specific binding 
was determined in the presence of an excess (1OpM) of unlabelled AII. 
After three washes with ice-cold BM, the cells were harvested into 
solubilisation buffer (Triton X-100 1% (v/v), glycerol 10% (v/v). BSA 
0.1% (w/v), HEPES 25 mM, pH 7.5) and cell-associated radioactivity 
was determined using a gamma counter. 
For the detection of PKC, cells were lysed directly into hot electro- 
phoresis sample buffer and cellular proteins were subjected to SDS- 
PAGE under reducing conditions. Following electroblotting onto ni- 
trocellulose, the a and B isofoxms of PKC were labelled with a murine 
monoclonal antibody (MC clone, Amersham). Immune complexes 
were detected by sequential incubation with a biotinylated sheep anti- 
mouse second antibody followed by [“‘Bstreptavidin (Amersham). 
3. Results 
A variety of agents known to regulate the proliferation 
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Fig. 1. Time course for the TPA-stimulated increase of [?]A11 binding 
to RIE-1 cells. (a) Cells were incubated with 3 nM (0) or 300 nM TPA 
(A) for the indicated times at 37°C. The specific binding of [‘251]AII was 
then determined. Each point represents the mean of duplicate determi- 
nations. (b) Cells were treated with 300 nM TPA at 37°C for the 
indicated times. PKC was then detected using immunoblotting as de- 
scribed in the text. 
of RIE-1 cells were tested for their ability to modulate 
the binding of [12SI]AII to the cells (Table 1). Pretreat- 
ment of the cells for 1 h at 37°C with EGF, IGF-1, 
insulin or transforming growth factor /?, (TGF-@,) had 
little or no effect on the subsequent binding of [‘251]AII 
to the cells at 4°C. However, pretreatment of the cells 
with TPA induced a large (2.7-fold) increase in [1251]AII 
binding. 
Table 1 
Effect of various agents on the binding of [‘zsI]AII to RIE-1 cells 
Addition Specific [“‘I]AII binding 
(% control f S.E.M.) 
\lo pretreatment 
Control 
EGF (20 &ml) 
IGF-I (100 rig/ml) 
Insulin (1 &ml) 
TGF;B, (1 @ml) 
TPA (30 nM) 
Cycloheximide pretreatment 
Control 
TPA (30 nM) 
lOOf 
96 f 1 
105f4 
108 f 5 
100 + 10 
274 f 7 
99+ 10 
244f9 
Cells were pre-treated with vehicle or cycloheximide (10 @ml) for 1 h 
at 37°C as indicated. Test agents were then added for a further 1 h at 
37°C and [‘251]AII binding was determined. Each value represents the 
mean of triplicate determinations (f S.E.M.). 
The time course of the effect of two different concen- 
trations of TPA on [‘251]AII binding is shown in Fig. la. 
At the higher concentration tested (300 nM), TPA stim- 
ulated a rapid increase in [12SI]AII binding which reached 
a peak value (3.6-fold over basal) 30 min after addition 
of the agent. In a total of twenty experiments, TPA stim- 
ulated a mean maximal 3.0-fold increase in [‘*‘I]AII 
binding. The maximal increase of binding (Fig. la) was 
sustained for a further 1 h, but thereafter decreased to 
the basal value by 6 h. In contrast to this biphasic re- 
sponse, treatment of the cells with 3 nM TPA increased 
[‘251]AII binding to a plateau value (1.7-fold over basal) 
at -2 h which was sustained until the end of the experi- 
ment at 6 h. 
The treatment period (6 h) required to reverse the 
increase of [‘251]AII binding induced by 300 nM TPA 
(Fig. la) correlated with the TPA treatment period (4-6 
h) required to down-regulate immunoreactive PKC in 
RIE-1 cells (Fig. lb). This rapid down-regulation of im- 
munoreactive PKC correlates with down-regulation of 
PKC activity [14]. The biphasic response of [‘2SI]AII 
binding to the higher dose (300 nM) of TPA (Fig. la) 
may therefore be explained by an initial activation of 
PKC (which increases [‘*‘I]AII binding), followed by a 
progressive down-regulation of the kinase which abro- 
gated the initial effect. Results obtained using various 
concentrations of TPA for short (45 min) and long (6 h) 
incubations were consistent with the summation of the 
effects of activation and down-regulation (data not 
shown). 
To confirm the role of PKC in the elevation of [‘*‘I]AII 
binding, RIE-1 cells were depleted of the kinase by pro- 
longed (16 h) incubation with a high dose (300 nM) of 
TPA. Subsequently, the addition of fresh TPA to these 
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Fig. 2. Dose-dependent increase of [‘ZSI]AII binding to RIE-1 cells by 
TPA. Cells were incubated for 16 h at 37°C with vehicle (0), or 300 
nM-TPA (0) to down-regulate PKC. Fresh TPA was then added for 
45 min at 37°C and specific [‘Z51]AII binding was determined. Each 
point represents the mean of triplicate determinations (k S.E.M.). 
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Fig. 3. TPA increases the number of angiotensin receptors on RIE-1 
cells. Cells were treated with vehicle (0) or 300 nM TPA (0) for 45 min 
at 37°C prior to overnight incubation at 4°C with [‘ZSI]AII in the 
concentration range 0. I-20 nM. After removing an aliquot of medium 
for the determination of free [‘Z51]AII, specific [‘Z51]AII binding was 
determined. The data is presented as a Scatchard [14] plot. Each point 
represents a single determination. 
PKC-depleted cells failed to induce any increase in bind- 
ing, whereas the agent increased binding to untreated 
cells (Fig. 2). This result confirms that the effect of TPA 
on [‘251]AII binding is mediated via PKC, and not via any 
other action of the agent. 
The TPA-induced increase of [‘251]AII binding to RIE- 
1 cells could result from an increase in the affinity and/or 
number of angiotensin receptors on the cells. The con- 
centration-dependent binding of [‘251]AII to control and 
TPA-treated cells was therefore investigated. Scatchard 
[15] analysis of the data is shown in Fig. 3. The plot for 
the TPA-pretreated cells is a linear slope essentially par- 
allel to that obtained using untreated cells, indicating 
that PKC increased the number of angiotensin receptors 
on RIE-1 cells (by 2.9-fold in this experiment) without 
having any significant effect on their binding affinity. 
Selective antagonists, which are used to classify angio- 
tensin receptors into AT,or AT2 subtypes [16,17], were 
employed to characterise the TPA-upregulated angioten- 
sin receptors on RIE-1 cells (Table 2). Incubation of 
untreated RIE-1 cells with the AT,-selective antagonist, 
DuP 753, inhibited the majority (84%) of specific 
[‘251]AII binding, indicating that most angiotensin recep- 
tors on these cells are the AT, subtype. In the experiment 
shown, DuP 753 also inhibited 46% of specific [1251]AII 
binding to the TPA-upregulated receptors. The mean 
inhibition by DuP 753 of specific [‘251]AII binding to 
TPA-upregulated receptors was 69% (range 4686%; 
n = 4). Hence, a significant proportion of the TPA- 
upregulated angiotensin receptors are the AT1 subtype. 
Interestingly, the remaining specific [“‘I]AII binding 
sites on untreated (16%) and TPA-treated (54%) RIE-1 
cells were insensitive to both DuP 753 and the 
AT,-selective angiotensin receptor antagonist, PD 
123319. These results suggest hat, in addition to AT, 
receptors, RIE-1 cells may also express ‘atypical’ angio- 
tensin receptors (similar to those described recently for 
Neuro-2A murine neuroblastoma cells [ l&19]), and that 
these ‘atypical’ receptors are also up-regulated by TPA. 
Because of its rapid time course, it seems unlikely that 
the up-regulation of [1251]AII binding to RIE-I cells re- 
sults from increased angiotensin receptor synthesis. This 
was confirmed by investigating the effect of the protein 
synthesis inhibitor, cycloheximide, on the TPA-mediated 
increase of [‘251]AII binding (Table 1). At the concentra- 
tion of cycloheximide used (10 ,@ml), the agent inhib- 
ited 95% of the incorporation of [35S]methionine into 
total RIE-1 cell proteins (data not shown). However, the 
same concentration of the agent failed to inhibit the 
TPA-mediated increase of [‘251]AII binding to RIE-1 
cells (Table 1). 
4. Discussion 
The existence of negative feedback regulation exerted 
by PKC on many G protein-coupled receptors to limit 
their activation is well documented [20]. In addition to 
an uncoupling of receptors from their effector systems, 
a common feature of this regulation is a reduction in 
receptor number and/or affinity [20]. In contrast, a PKC- 
induced up-regulation in receptor number, as reported 
here for the AT, angiotensin receptors on RIE-1 cells, is 
less common. Indeed, PKC-mediated up-regulation of 
angiotensin receptors has only previously been reported 
in primary cultures of rat neurones [21,22]. In common 
with RIE-1 cells, angiotensin receptor up-regulation in 
rat neuronal cultures was rapid and independent of pro- 
tein synthesis, although a doubling of receptor number 
was offset by a 50% reduction in their affinity [21,22]. 
However, rat neuronal cultures are heterogeneous (con- 
taining lO-15% non-neuronal cells [23]) and express both 
AT, and AT2 angiotensin receptors [24]. Consequently, 
Table 2 
Inhibition of [‘251]AII binding to TPA-treated RIE-1 cells by selective 
antagonists 
Specific [‘2SI]AII bound (% control + S.E.M.) 
Control TPA-pretreated 
Total Up-regulated 
Control lOOf 181 + S 81 +6 
DuP 753 (10 PM) 165 1 60 f 3 44f3 
PD 123319 (10pM) 101 + 5 175f 1 74 f 5 
Cells were treated with vehicle or 300 nM TPA for 45 min at 37°C. 
[‘251]AII binding was then determined in the presence of the indicated 
antagonists. The calculated binding of [‘ZSI]AII solely to the TPA- 
upregulated receptors is also shown. Each value represents the mean 
of triplicate determinations (+ S.E.M.). 
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the observed action of TPA on [1251]AII binding to these 
cultures may represent a summation of the effects of 
PKC on these two different cell types. 
In principle, there are several possible mechanisms 
whereby PKC could rapidly increase the binding of 
[1251]AII to AT, receptors on RIE-1 cells. Up-regulation 
may result from an increased availability (to extracellu- 
lar ligand) of a pool of preformed but previously ‘cryptic’ 
AT, receptors residing at or near the plasma membrane. 
Such receptors might usually exist in a conformation that 
renders them refractory to extracellular ligand, but un- 
dergo a PKC-mediated conformational change to allow 
ligand binding. Alternatively, PKC may induce a 
translocation to the cell surface of preformed AT, recep- 
tors from an intracellular compartment, analogous to 
the increased recycling of transferrin receptors to the 
plasma membrane induced by TPA in Chinese hamster 
ovary fibroblasts [25] or macrophages [26]. 
A direct effect of PKC on AT, angiotensin receptors 
is plausible since the intracellular carboxy-terminal tail 
of this receptor contains several potential serine/threo- 
nine phosphorylation sites [27]. Although PKC-medi- 
ated phosphorylation at any of these sites has yet to be 
demonstrated, the kinase is known to phosphorylate the 
intracellular domains of several other G protein-coupled 
receptors [28]. 
In conclusion, PKC increases the binding of [1251]AII 
to RIE-1 cells, due (in part) to an up-regulation in the 
number of AT1 angiotensin receptors. The rapidity of 
this response, and its independence from protein synthe- 
sis, suggest an increased availability (to extracellular 
ligand) of preformed, but previously ‘cryptic’, AT, 
angiotensin receptors. RIE-1 cells will provide a useful 
model system in which to further investigate this possi- 
bility. 
Acknowledgements: I thank Dr. A.N. Corps for reading the manuscript 
and for several useful suggestions, and DuPont and Parke Davis for the 
supply of angiotensin receptor antagonists. 
R. D. Smith IFEBS Letters 348 (1994) 51-54 
References 
VI 
14 
[31 
[41 
t51 
161 
t71 
181 
I91 
WI 
Vll 
P21 
[I31 
P41 
t151 
1161 
[I71 
1181 
P91 
[W 
m 
WI 
~231 
~241 
~251 
WI 
WI 
WI 
Rozengurt, E. (1986) Science 234, 161-166. 
Rozengurt, E. and Mendoza, S.A. (1985) J. Cell Sci. (suppl.) 3, 
229-242. 
Corps, A.N., Blakeley, D.M., Carr, J., Rees, L.H. and Brown, 
K.D. (1986) J. Endocrinol. 112, 151-159. 
Ross, R. and Vogel, A. (1978) Cell 14, 203-210. 
Brown, K.D., Blakeley, D.M. and Brigstock, D.R. (1989) FEBS 
Lett. 247, 227-231. 
Corps, A.N. and Brown, K.D. (1988) Biochem. J. 252, 119-125. 
Berridge, M.J. (1993) Nature 361, 315-325. 
Blay, J. and Brown, K.D. (1984) Cell Biol. Int. Rep. 8, 551-560. 
Blay, J. and Brown, K.D. (1986) J. Cell. Physiol. 129, 343-346. 
Corps, A.N. and Brown, K.D. (1987) J. Endocrinol. 113,285-290. 
Smith, R.D. (1994) Biochem. Mol. Biol. Int. 32, 923-932. 
Smith, R.D., Corps, A.N., Hadfield, K.M., Vaughan, T.J. and 
Brown, K.D. (1994) Biochem. J., in press. 
Thorell, J.I. and Johansson, B.G. (1971) Biochim. Biophys. Acta 
251, 363-369. 
Smith, R.D. (1994) B&hem. Mol. Biol. Int. 32, 307-314 
Scatchard, G. (1949) Ann. N.Y. Acad. Sci. 51, 66%672. 
Timmermanns, P.B.M.W.M., Carini, D.J., Chiu, A.T., Duncia, 
J.V., Price, W.A., Wells, G.J., Wang, P.C., Johnson, A.L. and 
Wexler, R.R. (1991) Am. J. Hypertens. 4, 275S-281s. 
Bumpus, F.M., Catt, K.J., Chiu, A.T., DeGasparo, M., Goodfri- 
end, T., Husain, A., Peach, M.J., Taylor, D.G. and Timmermanns, 
B.M.W.M. (1991) Hypertension 17, 72&721. 
Chaki, S. and Inagami, T. (1992) Biochem. Biophys. Res. Com- 
mun. 182, 388-394. 
Chaki, S. and Inagami, T. (1993) Mol. Pharmacol. 43, 603608. 
Sibley, D.R., Benovic, J.L., Caron, M.G. and Lefkowitz, R.J. 
(1988) Endocrine Rev. 9, 38-56. 
Sumners, C., Rueth, SM., Crews, F.T. and Raizada, M.K. (1987) 
J. Neurochem. 48, 19541961. 
Kalberg, C.J. and Sumners, C. (1990) Am. J. Physiol. 258, C610- 
C617. 
Raizada, M.K. (1983) Exp. Cell Res. 143, 351-357. 
Kang, J., Sumners, C. and Posner, P. (1992) Brain Res. 580, 317- 
324. 
McGraw, T.E., Dunn, K.W. and Maxfield, F. (1988) J. Cell Biol. 
106, 1061-1066. 
Buys, S.S., Keogh, E.A. and Kaplan, J. (1984) Cell 38, 569-576. 
Murphy, T.J., Alexander, R.W., Griendling, K.K., Runge, M.S. 
and Bernstein, K.E. (1991) Nature 351, 233-236. 
Kikkawa, U. and Nishizuka, Y. (1986) Annu. Rev. Cell Biol. 2, 
149-178. 
